Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: Sentinel network database study

• Published in: PloS one 2022-09, Vol.17 (9), p.e0265998-e0265998
• Main Authors: de Lusignan, Simon, Hobbs, F. D. Richard, Liyanage, Harshana, Sherlock, Julian, Ferreira, Filipa, Tripathy, Manasa, Heiss, Christian, Feher, Michael, Joy, Mark P
• Format: Article
• Language: English
• Subjects: Anticoagulants; Anticoagulants (Medicine); Atrial fibrillation; Biology and Life Sciences; Cardiac arrhythmia; Care and treatment; Coagulants; Complications and side effects; Computer programs; Drug therapy; Fibrillation; Health care; Health hazards; Health risks; Ischemia; Medicine and Health Sciences; Mortality; Patient outcomes; Primary care; Risk; Stroke; Stroke (Disease); Survival; Survival analysis; Warfarin
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0265998

We investigated differences in risk of stroke, with all-cause mortality as a competing risk, in people newly diagnosed with atrial fibrillation (AF) who were commenced on either direct oral anticoagulants (DOACs) or warfarin treatment. We conducted a retrospective cohort study of the Oxford Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database (a network of 500 English general practices). We compared long term exposure to DOAC (n = 5,168) and warfarin (n = 7,451) in new cases of AF not previously treated with oral anticoagulants. Analyses included: survival analysis, estimating cause specific hazard ratios (CSHR), Fine-Gray analysis for factors affecting cumulative incidence of events occurring over time and a cumulative risk regression with time varying effects.We found no difference in CSHR between stroke 1.08 (0.72-1.63, p = 0.69) and all-cause mortality 0.93 (0.81-1.08, p = 0.37), or between the anticoagulant groups. Fine-Gray analysis produced similar results 1.07 (0.71-1.6 p = 0.75) for stroke and 0.93 (0.8-1.07, p = 0.3) mortality. The cumulative risk of mortality with DOAC was significantly elevated in early follow-up (67 days), with cumulative risk decreasing until 1,537 days and all-cause mortality risk significantly decreased coefficient estimate:: -0.23 (-0.38-0.01, p = 0.001); which persisted over seven years of follow-up. In this large, contemporary, real world primary care study with longer follow-up, we found no overall difference in the hazard of stroke between warfarin and DOAC treatment for AF. However, there was a significant time-varying effect between anti-coagulant regimen on all-cause mortality, with DOACs showing better survival. This is a key methodological observation for future follow-up studies, and reassuring for patients and health care professionals for longer duration of therapy